Cargando…
The effects of a high-caloric protein-rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers: a randomized, double-blind pilot study
The prevalence of cardiac cachexia in chronic heart failure is approximately 5% to 15% and 18-month mortality rates can reach 50%. Treatment with angiotensin-converting enzyme inhibitors and beta-blockers may confer some benefit but no proven therapy exists. We tested the effects of an oral nutritio...
Autores principales: | Rozentryt, Piotr, von Haehling, Stephan, Lainscak, Mitja, Nowak, Jolanta U., Kalantar-Zadeh, Kamyar, Polonski, Lech, Anker, Stefan D. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3060643/ https://www.ncbi.nlm.nih.gov/pubmed/21475692 http://dx.doi.org/10.1007/s13539-010-0008-0 |
Ejemplares similares
-
Cachexia as a major public health problem: frequent, costly, and deadly
por: Farkas, Jerneja, et al.
Publicado: (2013) -
Kidney function in cachexia and sarcopenia: Facts and numbers
por: Okamura, Masatsugu, et al.
Publicado: (2023) -
Growth hormone, insulin-like growth factor 1, and insulin signaling—a pharmacological target in body wasting and cachexia
por: Trobec, Katja, et al.
Publicado: (2011) -
Cancer Cachexia and Related Metabolic Dysfunction
por: da Fonseca, Guilherme Wesley Peixoto, et al.
Publicado: (2020) -
COVID‐19: a major cause of cachexia and sarcopenia?
por: Morley, John E., et al.
Publicado: (2020)